Objective:
To evaluate the application of photobiomodulation (PBM) in treating retinal diseases, particularly age-related macular degeneration (AMD) and diabetic retinopathy (DR).
Approach:
- PBM Mechanism: PBM uses near-infrared and visible light to stimulate tissue repair by activating mitochondrial proteins, specifically cytochrome c oxidase, which increases adenosine triphosphate production, reduces reactive oxygen species, and increases antioxidant stability.
Key Findings:
- PBM is FDA-authorized for early-to-intermediate nonexudative AMD.
- Over 60% of PBM-treated patients showed improvement in visual acuity after 2 years.
- PBM does not replace established therapies for advanced AMD but may slow disease progression.
Interpretation:
PBM is a promising noninvasive treatment for intermediate AMD, focusing on enhancing mitochondrial activity and cellular resilience.
Limitations:
- The LIGHTSITE III trial did not assess PBM efficacy in advanced AMD.
- Long-term efficacy data for PBM remain limited, which may affect treatment decisions.
Conclusion:
PBM is being explored as an adjunctive treatment for retinal disorders, emphasizing the need for careful patient selection and adherence to treatment protocols.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
